Certain patients with germ cell cancer should receive life-long follow-up
the ONA take:
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death, and therefore should be candidates for life-long follow-up care, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers identified 268 patients with germ cell cancer who received more than one line of treatment for disseminated disease from the Danish Testicular Cancer database to evaluate late toxicity and survival.
Results showed that just more than half of patients died from germ cell cancer. The remaining patients had an increased risk for developing a second cancer, major cardiovascular disease, pulmonary disease, gastrointestinal disease, renal impairment, neurologic disorders, and death from other causes compared with patients who only underwent orchiectomy.
Researchers found that increasing age may contribute to treatment failure after second-line treatment in these patients.
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|